Sage Therapeutics (STU:SG7) Retained Earnings : €-2,805.10 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sage Therapeutics's retained earnings for the quarter that ended in Mar. 2025 was €-2,805.10 Mil.

Sage Therapeutics's quarterly retained earnings declined from Sep. 2024 (€-2,589.97 Mil) to Dec. 2024 (€-2,836.66 Mil) but then increased from Dec. 2024 (€-2,836.66 Mil) to Mar. 2025 (€-2,805.10 Mil).

Sage Therapeutics's annual retained earnings declined from Dec. 2022 (€-1,914.59 Mil) to Dec. 2023 (€-2,356.38 Mil) and declined from Dec. 2023 (€-2,356.38 Mil) to Dec. 2024 (€-2,836.66 Mil).

Sage Therapeutics Retained Earnings Historical Data

The historical data trend for Sage Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Retained Earnings Chart

Sage Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

-852.82

-1,323.42

-1,914.59

-2,356.38

-2,836.66

Sage Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Retained Earnings	Get a 7-Day Free Trial															-2,463.89	-2,583.55	-2,589.97	-2,836.66	-2,805.10

Sage Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Sage Therapeutics (STU:SG7) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Sage Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (STU:SG7) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

SAGE:USA SG7:Germany

Address

55 Cambridge Parkway, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Sage Therapeutics Headlines

No Headlines